Purple Biotech Reports Q1 2025 Financial Results

Ticker: PPBT · Form: 6-K · Filed: May 21, 2025 · CIK: 1614744

Sentiment: neutral

Topics: financial-results, quarterly-report, pharmaceuticals

TL;DR

Purple Biotech dropped Q1 2025 earnings on 5/21.

AI Summary

Purple Biotech Ltd. reported its first quarter 2025 financial results on May 21, 2025. The company, formerly known as Kitov Pharma Ltd., is based in Rehovot, Israel, and operates in the pharmaceutical preparations sector.

Why It Matters

This filing provides investors with the latest financial performance data for Purple Biotech Ltd., crucial for assessing the company's current health and future prospects.

Risk Assessment

Risk Level: low — This is a routine financial results filing with no new material events or significant changes indicated.

Key Players & Entities

FAQ

What is the primary purpose of this 6-K filing?

This 6-K filing is to report the Company's ("Purple Biotech Ltd.") first quarter 2025 financial results, as detailed in the attached press release.

When were the first quarter 2025 financial results announced?

The first quarter 2025 financial results were announced on May 21, 2025.

What was Purple Biotech Ltd. formerly known as?

Purple Biotech Ltd. was formerly known as Kitov Pharma Ltd. and Kitov Pharmaceuticals Holdings Ltd.

Where is Purple Biotech Ltd. located?

Purple Biotech Ltd.'s principal executive offices are located at 4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel.

Under which form does Purple Biotech Ltd. typically file annual reports?

Purple Biotech Ltd. indicates it files annual reports under Form 20-F.

Filing Details

This Form 6-K (Form 6-K) was filed with the SEC on May 21, 2025 regarding PURPLE BIOTECH LTD. (PPBT).

View full filing on EDGAR

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing